Aileron Therapeutics
Clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases.
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Aileron Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative medicines aimed at improving the outcomes and quality of life for cancer patients. The company operates in the biopharmaceutical market, specifically targeting historically undruggable targets with its proprietary platform of stabilized cell-permeating peptides. Aileron's lead product candidate, ALRN-6924, is designed to mimic the p53 tumor suppressor protein, disrupting its interactions with endogenous inhibitors to protect healthy cells during chemotherapy. This approach aims to prevent severe toxicities caused by off-target effects of cancer treatments.
Aileron Therapeutics serves cancer patients undergoing chemotherapy, particularly those with small cell lung cancer (SCLC). The company generates revenue through the development and potential commercialization of its drug candidates, as well as through public offerings of its common stock.
Keywords: biopharmaceutical, cancer, stabilized peptides, p53 protein, chemoprotection, ALRN-6924, clinical-stage, oncology, SCLC, drug development.
Tech stack
Investments by Aileron Therapeutics
Edit